Is Clorox Stock Worth Buying as GOJO Growth Meets Margin Pressure?
Clorox (CLX) reports Q4 net sales of $1.95B, up 2% YoY, with GOJO contributing 10 percentage points. Fiscal 2027 sales expected to rise 13-14%, with adjusted EPS at $5.70-$6.00. Gross margins declined due to inflation and higher costs. Organic sales growth is muted, with ERP comparisons aiding growth. CLX trades at 17.9X forward earnings, below its sub-industry multiple.
How this was made
The 30-second read
Why it matters
The guidance highlights a 13‑14% sales increase and 3‑8% EPS growth, but gross margin is expected to stay near 42%, indicating pressure on profitability.
Market read
Clorox's guidance may shape expectations for the broader consumer‑staples sector, especially regarding margin trends.
What to watch
Potential cost‑saving synergies from ERP investments and inflation‑hedging strategies are not fully quantified.
Background
Clorox recently acquired GOJO, expanding its health‑and‑hygiene portfolio, and now provides updated guidance for fiscal 2027.
Ticker impact
Clorox disclosed Q4 fiscal 2026 results and provided fiscal 2027 sales and earnings guidance, including the impact of the GOJO acquisition.
Potential modest downside or flat price action as investors weigh growth versus margin concerns.
Guidance is new but does not signal a major earnings beat; margin compression may limit upside.
Market effects
Consumer staples face mixed demand; Clorox's guidance may influence peers like PG and CHD.
U.S. consumer‑staples sector sentiment could be modestly affected.
Limited; primarily U.S. market focus.
Counterpoint
Despite margin pressure, the GOJO acquisition could unlock longer‑term growth if integration succeeds.
Key entities
- CompanyThe Clorox Company
US consumer‑staples firm (ticker CLX) reporting earnings and guidance.
